Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Tralau-Stewart and colleagues present a survey of the academic drug discovery environment in the United Kingdom in 2013, and discuss the major trends in comparison with the United States.
Several new drugs for advanced prostate cancer were approved in the past few years, and the pipelines are bristling with compounds that have diverse mechanisms of action. This article examines current and upcoming treatment modalities and provides a market outlook for prostate cancer.
This analysis of factors that affect the likelihood of success in drug research and development (R&D) indicates that scientific acumen and good judgment — particularly with regard to the early termination of less viable drug candidates — are crucial.
Forecasting of the future commercial value of drugs is a crucial activity that affects many decisions by pharmaceutical companies. However, this analysis indicates that many forecasts are wrong, often substantially.
Epigenetic alterations are found in a number of diseases. This analysis explores the different approaches that are being pursued to exploit the therapeutic potential of epigenetic targets, and provides an overview of the current epigenetics pipeline.
Agarwal and colleagues present an analysis of the overlap in the drug targets that are being pursued across the industry, which indicates that more than half of the novel drug targets in current pipelines are being pursued by only one company.
Dry age-related macular degeneration (AMD) is a major cause of vision loss in the elderly. Evans and Syed discuss the pipeline of therapies for dry AMD and the future of the market.
It is common for several companies to be simultaneously pursuing promising new targets, and this analysis investigates the relative importance of market entry order and therapeutic impact on commercial success for drugs in the same class.
This article analyses the evolution of the market for genomic sequencing technologies in the light of major reductions in sequencing costs and time, and the growth in potential pharmacogenomics applications.
Antibody–drug conjugates (ADCs), which allow cytotoxic drugs to be selectively targeted to cancer cells, are attracting considerable interest. This article analyses the pipeline of ADCs, as well as trends in collaborations and deals related to ADC platforms.
Products based on stem cells show promise in diverse therapeutic areas, including cardiovascular and autoimmune diseases. This article analyses the late-stage pipeline of stem cell therapies and provides a market overview.
There are an estimated 1.3 billion smokers worldwide, and nearly six million people die from tobacco-related diseases each year. This article discusses smoking cessation drugs that are in development or on the market, and provides an outlook for their commercial potential.
